Abstract
Polymorphism in genes coding drug-metabolizing enzymes may cause individual differences in the effectiveness and toxicity of many medications, including cytostatics. Although in recent years intensive treatment has positively influenced the prognosis in leukemias, many adverse effects resulting from nonspecific actions and the narrow therapeutic index of anti-cancer drugs are still observed during therapy. Determining selected gene polymorphisms may increase both the safety and the efficacy of treatment, and might help in developing individual therapies.
MeSH terms
-
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase / genetics*
-
Age Factors
-
Antimetabolites, Antineoplastic / adverse effects*
-
Child
-
Ferredoxin-NADP Reductase / genetics*
-
Genetic Predisposition to Disease
-
Humans
-
Methotrexate / adverse effects*
-
Patient Selection
-
Pharmacogenetics
-
Phenotype
-
Polymorphism, Genetic*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Recurrence
-
Reduced Folate Carrier Protein / genetics*
-
Risk Factors
-
Time Factors
-
Treatment Outcome
Substances
-
Antimetabolites, Antineoplastic
-
Reduced Folate Carrier Protein
-
SLC19A1 protein, human
-
methionine synthase reductase
-
Ferredoxin-NADP Reductase
-
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
-
Methotrexate